Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35914252.
- Also identified by DOI 10.7326/J22-0060.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hao Q, Aertgeerts B, Guyatt G, et al. <b>PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.</b> BMJ. 2022;377:e069066. 35508320.
Medical subject headings
- Anticholesteremic Agents
- Cardiovascular Diseases
- Hydroxymethylglutaryl-CoA Reductase Inhibitors